| Examiner-Initiated Interview Summary | Application No. | Applicant(s) |
|--|---|--|
| | 10/731,074 | ELOKDAH ET AL. |
| | Examiner | Art Unit |
| | Michael P. Barker | 1626 |
| All Participants: | Status of Application | on: <u>Pending</u> |
| (1) <u>Michael P. Barker</u> . | (3) | |
| (2) <u>Leslie Aberman</u> . | (4) | • |
| Date of Interview: 24 October 2005 | Time: <u>3:26 pm</u> | |
| Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant Exhibit Shown or Demonstrated: ☐ Yes If Yes, provide a brief description: | ☐ Applicant's representative) No | |
| Part I. | | |
| Rejection(s) discussed: N/A | | · |
| Claims discussed: 1-21 | | |
| Prior art documents discussed: See the attached PTO-892 | | |
| Part II. | | |
| SUBSTANCE OF INTERVIEW DESCRIBING TH See Continuation Sheet | E GENERAL NATURE OF WHA | T WAS DISCUSSED: |
| Part III. | | |
| ☑ It is not necessary for applicant to provide a significant directly resulted in the allowance of the applicant of the interview in the Notice of Allowability. ☑ It is not necessary for applicant to provide a significant result in resolution of all issues. A brief | ation. The examiner will provide separate record of the substance | a written summary of the substance of the interview, since the interview |
| | | |
| | | • |
| | | |
| | , | |
| | | |
| | | |
| (Examiner/SPE Signature) (| Applicant/Applicant's Represent | ative Signature – if appropriate) |

Continuation of Substance of Interview including description of the general nature of what was discussed:

- 1. Amend Claim 1 as follows: Page 27 of the Claims, line 27, delete "C1-C6 hydroxyalkyl,"; Page 28 of the Claims, line 1, delete "HSCH2-,".
- 2. Amend Claim 7 as follows: Page 30 of the Claims, line 1, after the words "in a mammal", add ", for treatment of thrombosis or fibrinolytic impairment in a mammal, wherein the thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion," (the remainder of Claim 7 is unchanged).
- 3. Amend Claim 13 as follows: Page 31 of the Claims, line 32, delete "A" and add "The"; line 32, after the word "method", add "of Claim 7".
- 4. Cancel Claims 9-12 and 14-21, pp. 31-33 of the Claims.